Skip to content

Study for the prognosis assessment value of biomark 12-HETE in patients with sepsis

Study for the prognosis assessment value of biomark 12-HETE in patients with sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018646
Enrollment
Unknown
Registered
2018-10-01
Start date
2018-11-01
Completion date
Unknown
Last updated
2018-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Sepsis group :no
Non-sepsis group :no
Health group:no

Sponsors

State Key Laboratory of Trauma, Burns, and Combined Injury, Department 1, Research Institute of Surgery, Daping Hospital, The Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 76 Years

Inclusion criteria

Inclusion criteria: Sepsis group: 1. Aged 18-76 years male and female; 2. Patients in ICU (diagnosed with sepsis or suspected sepsis or severe infection with organ damage patients); 3. Signing of the letter of informed consent. Non-sepsis group: including healthy people, patients with infections or trauma.

Exclusion criteria

Exclusion criteria: 1. patients with blood system diseases, abnormal lipid metabolism, and infectious diseases 2. pregnant and lactating women; 3. patients with mental disorders; 4. refuse to sign informed consent and refuse to provide information.

Design outcomes

Primary

MeasureTime frame
Plasma 12-HETE level;

Secondary

MeasureTime frame
Incidence of sepsis;Critical Illness score;28-day mortality rate of sepsis;health related quality of life score;inflammatory response;Biochemical target;immune function;

Countries

China

Contacts

Public ContactHuaping Liang

Research Institute of Surgery, Daping Hospital, Army Military Medical University, Chongqing

13638356728@163.com+86 13638356728

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026